Blueprint Medicines Total Revenue

Blueprint Medicines (BPMC) currently reports a total revenue of $560M as of March 2025. That compares with $280M in the prior-year period — up 99.2% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Blueprint Medicines's total revenue history and peer comparisons.

Blueprint Medicines's total revenue increased from $280M to $560M — a 99.2% year-over-year increase (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Blueprint Medicines's total revenue of $560M is lower than the Healthcare sector average of $110B. That is roughly 99.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Blueprint Medicines reported $560M in total revenue as of March 2025. That compares with $280M in the prior-year period — up 99.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $560M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Blueprint Medicines, and consider following BPMC for alerts when major investors trade the stock.